---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-007059"
form_type: "8-K"
ticker: "QTRX"
cik: "0001503274"
company_name: "Quanterix Corp"
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T17:48:27.174229+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Quanterix Q1 revenue $32.1M (+12.7%); net loss $10.1M; FDA breakthrough for P-tau217 test

## Summary
- Revenue $32.1M (+12.7% YoY); net loss $10.1M (increase of $4.0M YoY).
- GAAP gross margin 61.2% (up 170 bps); non-GAAP gross margin 54.5% (up 140 bps).
- FY 2024 guidance unchanged: revenue $139-$144M, GAAP gross margin 57-61%, non-GAAP 51-55%.
- Director Brian J. Blaser resigned board eff. May 3, 2024 to become CEO of QuidelOrtho; no disagreement.
- Simoa P-tau217 blood test granted FDA Breakthrough Device; Lilly launched CertuitAD test on SP-X platform.

## SEC filing metadata
- accession: 0001558370-24-007059
- form_type: 8-K
- ticker: QTRX
- cik: 0001503274
- company_name: Quanterix Corp
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503274/000155837024007059/0001558370-24-007059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503274/000155837024007059/tmb-20240502x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-007059
- JSON: https://secwatch.observer/filing/0001558370-24-007059.json
- Plain text: https://secwatch.observer/filing/0001558370-24-007059.txt

## Key facts
- Earnings Releases
  Quanterix Corp reported first quarter ended March 31, 2024 results: revenue $32.1 million. Guidance reaffirmed.
  - Period: first quarter ended March 31, 2024
  - Revenue: $32.1 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: to study and enable the early detection of neuro-pathologies such as Multiple Sclerosis, Parkinson’s, and Alzheimer’s disease.” First Quarter Financial Highlights ● Revenue of $32.1 million, an increase of 12.7% compared to $28.5 million in the prior year period. ● GAAP gross margin of 61.2%, an increase of approximately 170 basis points compared to the prior year
  evidence_url: https://www.sec.gov/Archives/edgar/data/1503274/000155837024007059/0001558370-24-007059-index.htm
- Executive change
  Brian J. Blaser resigned as Director at Quanterix Corp.
  - Action: resigned
  - Role: Director
  source text: On May 2, 2024, Brian J. Blaser notified Quanterix of his resignation from its Board of Directors, effective as of May 3, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1503274/000155837024007059/0001558370-24-007059-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.